"Recently, we have seen a lot of demand for AAV vectors," Gil-Goncalves told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC. However, she said current production methods "require a lot of material" and "impurity at the end of the process can be a concern."

Those two challenges can be overcome with Cevec's Elevecta platform because production does not require any plasmid or helper virus, according to Gil-Goncalves. Cevec provides manufacturing solutions for two of the most widely used gene therapy vectors: the CAP Ad platform for production of adenoviral vectors, and the Elevecta platform based on producer cell lines that can be used for AAV manufacturing.

At ASGCT 2022, CEVEC's Julia Hölper, senior scientist for cell line development, provided a poster presentation on stable helper virus-free Elevecta producer cells for AAV vector manufacturing.

Watch the video below to learn more.

Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...

Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...

Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectors
It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors,...